CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 113,425	$ 15,375	$ 246,447	$ 67,615
Cost and operating expenses:
Cost of sales	2,155		3,690
Research and development	47,570	59,181	149,267	154,885
Selling, general and administrative	37,744	33,623	114,116	74,064
Total cost and operating expenses	87,469	92,804	267,073	228,949
Income (loss) from operations	25,956	(77,429)	(20,626)	(161,334)
Interest income	7,383	1,539	14,775	2,183
Interest expense on term loan	(2,539)		(5,857)
Non-cash interest expense on liability related to the sale of future royalties and term loan	(1,054)	(867)	(2,986)	(3,194)
Other (expense) income, net	(164)	(998)	(109)	(1,576)
Net loss before income taxes	29,582	(77,755)	(14,803)	(163,921)
Income tax benefit	(1,166)		(289)
Net loss	$ 30,748	$ (77,755)	$ (14,514)	$ (163,921)
Net income (loss) per common share - basic (Note B)	$ 0.10	$ (0.31)	$ (0.05)	$ (0.65)
Net income (loss) per common share - diluted (Note B)	$ 0.10	$ (0.31)	$ (0.05)	$ (0.65)
Basic weighted average common shares outstanding (in shares)	273,341	253,511	265,265	253,371
Diluted weighted average common shares outstanding (in shares)	287,590	253,511	265,265	253,371
License and milestone fees
Revenues:
Total revenues	$ 51	$ 7,382	$ 15,122	$ 45,247
Non-cash royalty revenue related to the sale of future royalties
Revenues:
Total revenues	7,355	$ 7,993	17,936	21,537
Research and development support
Revenues:
Total revenues	855		1,310	$ 831
Product revenue, net
Revenues:
Total revenues	$ 105,164		$ 212,079